Press releases

31 July, 2020

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI), today announced an increase of the number of shares and votes in the company of 26,666,666 as a result of a performed directed rights issue, resolved by the Board o ...

15 June, 2020

Regulatory

Abliva completes the directed issue of MSEK 20 to Hadean Ventures

On April 22, 2020, the Board of Directors of Abliva AB (publ) ("Abliva" or the "Company") resolved, supported by the authorization granted at the Annual General Meeting on April 25, 2019, on a directe ...

29 May, 2020

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announced an increase of the number of shares and votes in Abliva of 83,720,875 as a result of a fully performed preferential rights issue, resolved by the Boa ...

20 May, 2020

Last day of trading with BTA in NeuroVive

The rights issue in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”) has today been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and paid subscribed sh ...

5 May, 2020

Regulatory

NeuroVive publishes outcome in rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company ...

24 April, 202019 February, 2024

Regulatory

Publication of supplementary prospectus related to NeuroVive’s rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has prepared a supplementary prospectus (the “Supplementary Prospectus”) to the prospectus that was approved and regi ...

22 April, 2020

Regulatory

NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a directed issue of shares totaling around MSEK 20 to Hadean Ventures (“Directed Issue”). Hade ...

3 April, 202019 February, 2024

Regulatory

NeuroVive publishes prospectus and new financial information included in the prospectus in connection with forthcoming rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has in connection with the forthcoming issue of shares with preferential rights for existing shareholders, announced ...

19 February, 2020

Regulatory

NeuroVive proposes a rights issue of MSEK 74 and accelerates the clinical development of KL1333

Lund, Sweden, 19 February 2020, NeuroVive Pharmaceutical AB (Nasdaq Stockholm) today announced that the Board of Directors of NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”) has reso ...

29 March, 2019

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 29 March 2019 - NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 22,594,467 as a result of ...

7 March, 2019

Regulatory

NeuroVive receives SEK 28.2 Million in a directed new share issue

Lund, Sweden, 7 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has successfully conducted a directed new issue of shares, which has rais ...

28 February, 2019

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 28 February 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 71,661,048 as a result ...